Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 10193 - 10200 of 12007 results
A Lesson on the ADA: Engaging in Good Faith in the Interactive Process is Essential
August 12, 2014| Blog| Viewpoint
Governor Christie Signs Scaled-Back Opportunity to Compete Act - New Jersey's Ban the Box Bill
August 12, 2014| Blog| Viewpoint
IRS Relaxes and Clarifies Renewable Energy Tax Credit Eligibility Requirements for Projects Under Construction
August 12, 2014| Blog| Viewpoint
CMS Temporarily Closes the Open Payments System
August 12, 2014| Blog| Viewpoint
PREPA Bondholders Seek Summary Judgment Invalidating Puerto Rico’s Public Corporation Bankruptcy Legislation
August 12, 2014| Blog| Viewpoint
Colorado Federal Court Walks Back Rejection of ADEA Waiver in RIF Case
August 11, 2014| Blog| Viewpoint
Do as I Say, Not as I Do: Even the Government Falls Victim to Wage and Hour Violations Sometimes
August 11, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|